LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

Search

Novo Nordisk A-S

Gesloten

SectorGezondheidszorg

55.6 -0.82

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

55.36

Max

55.62

Belangrijke statistieken

By Trading Economics

Inkomsten

-2.5B

27B

Verkoop

-1.2B

77B

K/W

Sectorgemiddelde

15.409

35.69

EPS

6.53

Dividendrendement

2.84

Winstmarge

34.484

Werknemers

78,387

EBITDA

-2.5B

44B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+7.79% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.84%

3.08%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

52B

268B

Vorige openingsprijs

56.42

Vorige sluitingsprijs

55.6

Nieuwssentiment

By Acuity

74%

26%

341 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Novo Nordisk A-S Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 aug 2025, 13:52 UTC

Belangrijke Marktbewegers

GoodRx Partners With Novo Nordisk to Lower Cost of Weight-Loss Drugs

18 aug 2025, 09:23 UTC

Belangrijke Marktbewegers

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

18 aug 2025, 09:23 UTC

Belangrijke Marktbewegers

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

6 aug 2025, 06:52 UTC

Winsten

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

6 aug 2025, 06:21 UTC

Winsten

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

22 sep 2025, 13:43 UTC

Acquisities, Fusies, Overnames

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

18 sep 2025, 12:30 UTC

Marktinformatie

Correction to Novo Nordisk Market Talk

18 sep 2025, 12:00 UTC

Marktinformatie

Novo Nordisk's Prospects Could Turn Around -- Market Talk

18 sep 2025, 08:55 UTC

Populaire aandelen

Stocks to Watch Thursday: Nvidia, PayPal, Novo Nordisk -- WSJ

11 sep 2025, 10:59 UTC

Marktinformatie

Novo Nordisk Investors Cheer Plans to Slim Organization -- Market Talk

10 sep 2025, 13:24 UTC

Winsten

Ozempic Maker Novo Nordisk to Cut 9,000 Jobs -- Update

10 sep 2025, 09:16 UTC

Populaire aandelen

Stocks to Watch Wednesday: Oracle, GameStop, Novo Nordisk -- WSJ

2 sep 2025, 09:14 UTC

Populaire aandelen

Stocks to Watch Tuesday: Nestlé, Novo Nordisk, Nvidia -- WSJ

21 aug 2025, 08:49 UTC

Winsten
Populaire aandelen

Stocks to Watch Thursday: Meta, Coty, Walmart, Novo Nordisk -- WSJ

18 aug 2025, 09:23 UTC

Populaire aandelen

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth -- WSJ

8 aug 2025, 05:32 UTC

Marktinformatie

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 aug 2025, 11:32 UTC

Winsten

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 aug 2025, 11:03 UTC

Winsten

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 aug 2025, 10:41 UTC

Winsten

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6 aug 2025, 20:34 UTC

Winsten

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6 aug 2025, 08:45 UTC

Winsten

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

6 aug 2025, 07:19 UTC

Marktinformatie
Winsten

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

6 aug 2025, 05:50 UTC

Winsten

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

6 aug 2025, 05:48 UTC

Winsten

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

6 aug 2025, 05:46 UTC

Winsten

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

6 aug 2025, 05:38 UTC

Winsten

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

6 aug 2025, 05:37 UTC

Winsten

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

6 aug 2025, 05:36 UTC

Winsten

Novo Nordisk 2Q Gross Margin 83.3% Vs 84.9%, Op Margin 43.5% Vs 38.1%

6 aug 2025, 05:35 UTC

Winsten

Novo Nordisk: Taking Measures to Sharpen Commercial Execution Further, Ensure Efficiencies in Cost Base

6 aug 2025, 05:34 UTC

Winsten

Novo Nordisk: Continues Global Rollout of Wegovy to More Markets, Investing in Commercial Activities

Peer Vergelijking

Prijswijziging

Novo Nordisk A-S Prognose

Koersdoel

By TipRanks

7.79% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 59.94 USD  7.79%

Hoogste 70 USD

Laagste 50 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Novo Nordisk A-S - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

8 ratings

5

Buy

3

Hold

0

Sell

Technische score

By Trading Central

62.63 / 69.23Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

341 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat